NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
April 11 2022 - 6:50AM
Business Wire
Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm to be Featured on “Get Ready, Gorgeous with
Ali” on April 12 at 8 a.m. Eastern Time
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality, scientifically
formulated eyecare and skincare products, announces that Chief
Product Officer Audrey Kunin, MD will return to the QVC network as
a live on-air guest to discuss DERMAdoctor’s problem-solving eczema
treatment. The revolutionary Calm Cool + Corrected 1% Colloidal
Oatmeal Eczema + Dermatitis Clinical Repair Balm will be featured
on “Get Ready, Gorgeous with Ali” on Tuesday, April 12 at 8 a.m.
Eastern time.
“After successfully introducing this proprietary, scientifically
formulated and highly effective product to QVC viewers last month,
it’s very exciting to be asked back to highlight the significant
benefits of Calm Cool + Corrected 1% Colloidal Oatmeal Eczema +
Dermatitis Clinical Repair Balm to QVC’s vast audience,” said Dr.
Kunin. “Eczema is a significant concern for many, affecting an
estimated 31 million Americans. Our Calm Cool + Corrected Eczema
balm provides temporary relief of minor irritations and itching,
while maximizing hydration to calm and soothe affected skin
anywhere on the body.”
Dr. Kunin is a board-certified dermatologist, author, clinician,
educator, television personality and recognized trailblazer in the
skincare industry. She founded DERMAdoctor to provide simple, easy,
at-home clinical skin therapy that delivers significant, measurable
results for common skincare concerns that have been overlooked by
the beauty industry.
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm is formulated with a special form of
eczema-active 1% colloidal oatmeal with enhanced beta glucan,
together with an advanced complex of ceramides and essential lipids
and dermatologic botanicals. Calm Cool + Corrected 1% Colloidal
Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the
National Eczema Association (NEA) Seal of Acceptance™, which is
granted in recognition of products that meet the NEA’s rigorous
standards for providing benefits and improving the quality of life
for people with eczema and sensitive skin.
About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray in the eyecare
market. In November 2021, NovaBay acquired DERMAdoctor, LLC, a
company offering more than 30 dermatologist-developed skincare
products sold through traditional domestic retailers, digital
beauty channels and international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220411005036/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024